Innovation Tracking Factbook 2016 - An Assessment of the Pharmaceutical Pipeline
|出版商||CBR Pharma Insights||商品編碼||363445|
|出版日期||內容資訊||英文 70 Pages
|革新追蹤概況 2016年:醫藥品開發平台的評估 Innovation Tracking Factbook 2016 - An Assessment of the Pharmaceutical Pipeline|
|出版日期: 2016年06月01日||內容資訊: 英文 70 Pages||
GBI Research's latest report, "Innovation Tracking Factbook 2016 - An Assessment of the Pharmaceutical Pipeline" is a comprehensive, granular analysis of the 20,756 products currently in the pharmaceutical industry pipeline, from the Discovery stage through to Pre-registration and split into therapy areas and key indications. This pipeline is also benchmarked against its size across each segment in 2015, and an assessment of the level of first-in-class innovation is provided. In addition, a detailed contextual analysis of the key drivers of this pipeline is provided, in addition to an assessment of companies present in the pipeline and historical deal value and volume.
Innovation, particularly the development of new products, is a crucial element of the pharmaceutical industry. The market is highly research-intensive, being deeply reliant on a high level of R&D investment and a strong product pipeline to maintain growth and ensure long-term revenue generation. Without successful innovation, which can be broadly defined as the market launch of novel therapeutic molecules that cost-effectively treat or cure diseases, the industry would face a substantial long-term decline in revenue.
A particular focus of this report is placed on analysis of the development of innovative drugs, specifically first-in-class innovation. Over recent decades, in addition to an increase in the yearly number of new chemical entity approvals by the FDA, the number and proportion of these approvals that were first-in-class at the time of approval have also increased. The proportion of first-in-class approvals has increased steadily each year since 1994, with the exception of the years 2005-2008, when the proportion was relatively high.
This report will allow you to -